Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina – The IMPROVE-ISCHEMIA Phase 2 clinical trial met the primary endpoint of tolerability and safety; 8-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement in...

Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina – IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...

Imbria Pharmaceuticals Completes Enrollment in Phase 2 IMPROVE-HCM Trial of Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy – Enrollment exceeded expectations, thus highlighting the large unmet need in non-obstructive hypertrophic cardiomyopathy – – IMPROVE-HCM topline data expected in 4Q 2023 – – Topline Phase 2 data...

Imbria Pharmaceuticals to Participate in SVB Securities Biopharma Private Company Connect BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...

Imbria Pharmaceuticals to Participate in BMO’s Fall Private Company Showcase BOSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...